Diabetes Management Products: Trends, Part 1
Two of the trends around diabetes management products in the US are the growing uptake of continuous glucose monitoring and innovations in automated insulin delivery.
Continuous Glucose Monitoring (CGM)
- Continuous glucose monitoring systems are considered essential for the treatment of insulin-dependent diabetes. They are supposed to bring better long-term outcomes thanks to monitoring glucose levels in real-time, which allows for making better short-term decisions. Due to recent regulatory changes and more innovative products coming to the market, the CGM technology uptake is growing.
- The emergence of continuous glucose monitoring systems has fueled the growth of the whole US diabetes monitoring market.
- According to Market Reports World, continuous glucose monitoring is one of the key trends in the North American blood glucose monitoring market. It is the best tool to achieve glycemic balance and avoid hypoglycemia for patients using insulin pumps or multiple daily injections therapy.
- In 2018, the FDA added a new category, "integrated continuous glucose monitoring systems," which makes it easier to bring CGM-related innovations to the market.
- In late 2017, around 24% of patients with documented type 1 diabetes used CGM devices. However, the percentage has and will be growing with technological advancements and "broadening of inclusion criteria."
- The United States accounts for the largest share of the North American $1.12 billion CGM market.
- While the 2019 share is not available, in 2018, it was 97.44%.
- The country is expected to maintain its dominance due to the highest prevalence of diabetes and good conditions for adapting new technologies.
- The CGM market is expected to grow by 27.18% in the US until 2025, compared to 8.45% in the entire North America.
Company at the Forefront
- DexCom, a San Diego-based company focused on innovative CGM systems, is at the forefront of the trend.
- Its G5 Mobile CGM Systems were the first that the FDA approved for "making diabetes treatment decisions without the need for a confirmatory blood glucose measurement," while their G6 was the first in the new CGM-related medical device category created by the FDA.
Automated Insulin Delivery (AID)
- According to experts from DiabetesMine's 2019 Innovation Summit, 2020 will be the year of automated insulin delivery (AID), also known as Bionic Pancreas, artificial pancreas, hybrid closed loop, and predictive low glucose suspend. It involves an algorithm and a monitoring device that adjusts an insulin dose and delivers it via a pump.
- Also, developments in AID, such as DexCom's acquisition of TypeZero Technologies and the FDA approval of AID device by Tandem Diabetes Care, were included among key news in reports on the diabetes management devices market.
- Currently, only three AID solutions are available in the US market — Medtronic MiniMed 670G, Tandem Basal-IQ, and Tandem Control-IQ. In 2020, between three and five products from this category will be launched.
- Until 2020, the AID devices that are in the market are capable of stopping or reducing insulin delivery when glucose is low, and "adjust basal insulin delivery depending on whether the user’s glucose is trending up or down." With the launch of Tandem Control-IQ, they will also deliver correction boluses.
- The global artificial pancreas device system market is expected to grow at a CAGR of 15.5%. While the US-specific growth predictions are not available, it is the largest region and will be the fastest-growing one.
- Therefore, it accounts for the largest share of the $126.8 million artificial pancreas market (the figure includes Europe and North America), which will grow to $320.2 million in 2027.
- The drivers of this trend include high competition between key players to bring innovative products to the market, as well as favorable market conditions in the US, which include good reimbursement policies and easy uptake of emerging technologies.
- In 2019, Diabeloop raised $34 million in Series B to finance the deployment of its AID system. In 2020, Bigfoot Biomedical raised $45 million in Series C to finance the development of its digital insulin-dosing platform.
Company at the Forefront
- Tandem Diabetes Care is one of the companies at the forefront of the trend.
- It is San Diego-based and solely dedicated to developing diabetes solutions.
- One of its AID systems, Tandem Basal-IQ, was approved by the FDA in December 2019.
- A more advanced system, Tandem Control-IQ, launched at the beginning of this year. It is the first one to provide correction boluses.
Trends were selected based on being included in multiple reports on the diabetes devices and diabetes monitoring industries, and being mentioned in expert articles.